Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bufanolides
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
China
Drugs, Chinese Herbal
/ administration & dosage
Female
Humans
Karnofsky Performance Status
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Quality of Life
Randomized Controlled Trials as Topic
Survival Analysis
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
17
9
2019
Statut:
ppublish
Résumé
Cinobufotalin injection (CFI), a kind of Chinese medicine, has been considered as a promising complementary therapy option for advanced non-small cell lung cancer (NSCLC), but their efficacy and safety remain controversial. This study aimed to systematically evaluate the efficacy and safety of CFI and chemotherapy-combined therapy for advanced NSCLC. Clinical trials were searched from Web of Science, Cochrane Library, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biological Medicine Database (CBM), Chinese Medical Citation Index (CMCI), Wanfang database and Chinese Scientific Journal Database (VIP). Main measurements, including therapeutic efficacy, quality of life (QoL) and adverse events, were extracted from the retrieved publications and were systematically evaluated. The 29 trials including 2300 advanced NSCLC patients were involved in this study. Compared with chemotherapy alone, its combination with CFI significantly prolonged the patients' 1-, 2- and 3-year overall survival rate (OS) (1-year OS, OR = 1.94, 95% CI = 1.42-2.65, P < .0001; 2-year OS, OR = 2.31, 95% CI = 1.55-3.45, P < .0001; 3-year OS, OR = 4.69, 95% CI = 1.78-12.39, P = .002) and improved patients' overall response (ORR, OR = 1.84, CI = 1.54-2.18, P < .00001), disease control rate (DCR, OR = 2.09, 95% CI = 1.68-2.60, P < .00001) and QoL (quality of life improved rate, QIR, OR = 2.64, 95% CI = 1.98-3.52, P < .00001; karnofsky performance score, KPS, OR = 10.97, 95% CI = 5.48-16.47, P < .0001). Most adverse events caused by chemotherapy were obviously alleviated (P < .05) when CFI was also applied to patients. The combination of CFI and chemotherapy is safe, and is more effective in treating NSCLC than chemotherapy alone. Therefore, CFI mediated therapy could be recommended as an adjuvant treatment method for NSCLC.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Cinobufotalin injection (CFI), a kind of Chinese medicine, has been considered as a promising complementary therapy option for advanced non-small cell lung cancer (NSCLC), but their efficacy and safety remain controversial. This study aimed to systematically evaluate the efficacy and safety of CFI and chemotherapy-combined therapy for advanced NSCLC.
METHODS
METHODS
Clinical trials were searched from Web of Science, Cochrane Library, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biological Medicine Database (CBM), Chinese Medical Citation Index (CMCI), Wanfang database and Chinese Scientific Journal Database (VIP). Main measurements, including therapeutic efficacy, quality of life (QoL) and adverse events, were extracted from the retrieved publications and were systematically evaluated.
RESULTS
RESULTS
The 29 trials including 2300 advanced NSCLC patients were involved in this study. Compared with chemotherapy alone, its combination with CFI significantly prolonged the patients' 1-, 2- and 3-year overall survival rate (OS) (1-year OS, OR = 1.94, 95% CI = 1.42-2.65, P < .0001; 2-year OS, OR = 2.31, 95% CI = 1.55-3.45, P < .0001; 3-year OS, OR = 4.69, 95% CI = 1.78-12.39, P = .002) and improved patients' overall response (ORR, OR = 1.84, CI = 1.54-2.18, P < .00001), disease control rate (DCR, OR = 2.09, 95% CI = 1.68-2.60, P < .00001) and QoL (quality of life improved rate, QIR, OR = 2.64, 95% CI = 1.98-3.52, P < .00001; karnofsky performance score, KPS, OR = 10.97, 95% CI = 5.48-16.47, P < .0001). Most adverse events caused by chemotherapy were obviously alleviated (P < .05) when CFI was also applied to patients.
CONCLUSION
CONCLUSIONS
The combination of CFI and chemotherapy is safe, and is more effective in treating NSCLC than chemotherapy alone. Therefore, CFI mediated therapy could be recommended as an adjuvant treatment method for NSCLC.
Identifiants
pubmed: 31464940
doi: 10.1097/MD.0000000000016969
pii: 00005792-201908300-00052
pmc: PMC6736171
doi:
Substances chimiques
Bufanolides
0
Drugs, Chinese Herbal
0
cinobufotalin
L0QBZ37386
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16969Références
Complement Ther Med. 2016 Feb;24:55-62
pubmed: 26860802
Stat Med. 2012 Dec 20;31(29):3805-20
pubmed: 22763950
Curr Cancer Drug Targets. 2019;19(3):199-209
pubmed: 29714142
Cancer Med. 2018 May 23;:
pubmed: 29790669
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Biochemistry. 2018 Aug 28;57(34):5105-5116
pubmed: 29957995
Steroids. 2012 Sep;77(11):1069-74
pubmed: 22583912
Oncotarget. 2017 Jul 11;8(28):45164-45177
pubmed: 28404886
Oncotarget. 2016 Dec 27;7(52):86500-86510
pubmed: 27863436
Proc Soc Exp Biol Med. 1951 Feb;76(2):372-4
pubmed: 14827929
J Am Chem Soc. 2015 Nov 11;137(44):14067-70
pubmed: 26517568
Onco Targets Ther. 2016 Sep 16;9:5693-5698
pubmed: 27695347
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cochrane Database Syst Rev. 2014 Nov 17;(11):CD009948
pubmed: 25400254
Chem Biol Interact. 2012 Sep 30;199(3):154-60
pubmed: 22898211
Chin J Integr Med. 2014 Mar;20(3):179-83
pubmed: 24615210
Int J Cancer. 2018 Jun 1;142(11):2344-2354
pubmed: 29318609
Sci Rep. 2017 Jun 28;7(1):4355
pubmed: 28659623
Tumour Biol. 2015 Aug;36(8):5763-71
pubmed: 25724183
Biochem Biophys Res Commun. 2014 Sep 26;452(3):768-74
pubmed: 25201730
J Evid Based Med. 2015 Feb;8(1):2-10
pubmed: 25594108
Cancer. 2009 Nov 15;115(22):5309-18
pubmed: 19701908